 <h1>Synagis Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>palivizumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about palivizumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Synagis.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to palivizumab: intramuscular solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, palivizumab (the active ingredient contained in Synagis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking palivizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Bluish color of the fingernails, lips, skin, palms, or nail beds</li>
<li>blurred vision</li>
<li>confusion</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>hives or welts</li>
<li>irregular, fast or slow, or shallow breathing</li>
<li>itching</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of strength or energy</li>
<li>muscle pain or weakness</li>
<li>redness of the skin</li>
<li>shortness of breath</li>
<li>skin rash</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>unresponsiveness</li>
<li>unusual tiredness or weakness</li>
<li>wheezing</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>pinpoint red spots on the skin</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of palivizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end intramuscular solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to palivizumab: intramuscular powder for injection, intramuscular solution</i></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Arrhythmia (during studies of congenital heart disease patients)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylaxis, anaphylactic shock (sometimes fatal)</p>
<p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria</p>
<p><b>Frequency not reported</b>: Pruritus<sup>[Ref]</sup></p><h3>General</h3><p>The most serious adverse reactions are anaphylaxis and other acute hypersensitivity reactions.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Thrombocytopenia (mild), eosinophilia (mild)</p>
<p><b>Postmarketing reports</b>: Severe thrombocytopenia (platelet count less than 50,000/microliter)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Convulsions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Cyanosis during studies of congenital heart disease patients</p>
<p><b>Postmarketing reports</b>: Dyspnea, asthma, bronchospasm<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Synagis (palivizumab)." Ross Product Division Pharmaceuticals, Columbus, OH. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Boeckh M,  Berrey MM,  Bowden RA,  Crawford SW,  Balsley J,  Corey L "Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants." J Infect Dis 184 (2001): 350-4</p><p id="ref_4">4. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Synagis (palivizumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: immune globulins</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Synagis &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Respiratory Syncytial Virus</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to palivizumab: intramuscular powder for injection, intramuscular solution</i></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Arrhythmia (during studies of congenital heart disease patients)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylaxis, anaphylactic shock (sometimes fatal)</p><p><b>Postmarketing reports</b>: Angioedema<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site reactions<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria</p><p><b>Frequency not reported</b>: Pruritus<sup>[Ref]</sup></p><h3>General</h3><p>The most serious adverse reactions are anaphylaxis and other acute hypersensitivity reactions.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Uncommon</b> (0.1% to 1%): Thrombocytopenia (mild), eosinophilia (mild)</p><p><b>Postmarketing reports</b>: Severe thrombocytopenia (platelet count less than 50,000/microliter)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Uncommon</b> (0.1% to 1%): Convulsions<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Cyanosis during studies of congenital heart disease patients</p><p><b>Postmarketing reports</b>: Dyspnea, asthma, bronchospasm<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Synagis (palivizumab)." Ross Product Division Pharmaceuticals, Columbus, OH. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Boeckh M,  Berrey MM,  Bowden RA,  Crawford SW,  Balsley J,  Corey L "Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants." J Infect Dis 184 (2001): 350-4</p><p id="ref_4">4. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><h2>More about Synagis (palivizumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: immune globulins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Synagis &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Respiratory Syncytial Virus</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>